UCI School of Medicine

Name

UCI School of Medicine

Legal name

University of California, Irvine School of Medicine

Website

https://medschool.uci.edu

Company type

Public

Founded year

1965

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Medical Education

NAICS

Colleges, Universities, and Professional Schools (6113), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Medical Schools (MD/DO Granting) (EDAHAGAB)

akta.pro secondary industries

Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA), Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

Keywords

• Medical education
• Biomedical research
• Clinical trials
• Graduate medical education
• Continuing medical education

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. Medical Education Tuition and Fees: Revenue from educating over 500 medical students annually, plus graduate (PhD, MS) students and postdoctoral scholars through tuition, fees, and associated programs.
2. Healthcare Services: Revenue generated through UCI Medical Center and affiliated institutions providing clinical care to patients; includes outpatient services, inpatient care, and specialty medical services.
3. Research Grants and Funding: Federal and institutional research funding from agencies including NIH (BRAIN Initiative, NIA, NIMH), supporting Alzheimer’s disease research, neural circuit mapping, viral vector development, and clinical trials. Major grants include $10M NIH tau protein study, $3.8M BRAIN Initiative grant, and multiple R01/R24 awards.
4. Continuing Medical Education (CME): Revenue from CME programs offering educational activities and CME credits for practicing physicians and healthcare professionals, including conferences, symposia, and workshops.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

UCI School of Medicine educates physicians and biomedical researchers through MD, PhD, MD/PhD, master's, residency, fellowship, and Continuing Medical Education programs across 24 basic science and clinical departments. It conducts NIH-funded translational research in neuroscience, Alzheimer's disease, depression, ALS, and infectious disease through centers such as the Center for Neural Circuit Mapping and the Noel Drury Institute, and delivers clinical care through UCI Medical Center and affiliated hospitals.

Product overview

UCI School of Medicine is a medical education institution offering a comprehensive portfolio of educational programs and research centers. The core educational offerings include MD, PhD, MD/PhD, and Master's degree programs, alongside Graduate Medical Education (residency/fellowship) and Continuing Medical Education for practicing physicians. Research is conducted through specialized centers including the Center for Neural Circuit Mapping (CNCM) focused on neural circuit mapping technologies, and the Noel Drury Institute for Translational Depression Discoveries. The school provides clinical trials services and healthcare through UCI Medical Center. All medical education programs are LCME-accredited. Programs emphasize translational research applying scientific discoveries to clinical care, with particular strengths in neuroscience, Alzheimer's disease, and precision medicine.

Differentiator

Problem solved

Functional benefit

Brands

• Noel Drury, M.D. Institute for Translational Depression Discoveries: Translational research institute focused on depression treatment and discovery
• Center for Neural Circuit Mapping (CNCM)
• Sue & Bill Gross Stem Cell Research Center

Products and services

• Medical Degree (MD) Program Four-year medical education program leading to an MD degree, ranked among the top 50 U.S. medical schools for research by U.S. News & World Report, with hands-on clinical training at UCI Medical Center and community clinics; intended for prospective medical students.
• PhD and MD/PhD Programs Doctoral research degree programs in basic and clinical sciences, training students for careers in biomedical research, biomedical technology, or academic education; intended for prospective graduate researchers.
• Master's Programs Graduate-level master's degree programs in biomedical research and related fields, for students seeking advanced training in clinical and basic sciences.
• Graduate Medical Education (Residency and Fellowship) Postgraduate medical training across 24 departments spanning basic science research to clinical medical and surgical specialties, with a 95% residency match rate; intended for physicians entering residency or fellowship.
• Continuing Medical Education (CME) Ongoing professional development offering CME credits for practicing physicians and healthcare professionals through conferences, journal clubs, symposia, and community lecture series.
• LCME-Accredited Medical Education Medical education program accredited by the Liaison Committee on Medical Education (LCME); first accredited in 1961 and most recently granted full eight-year reaccreditation in January 2025, with next survey visit scheduled for AY 2032-33.
• Clinical Trials Services Clinical trial recruitment and management services enabling patient enrollment in cutting-edge research studies and experimental treatments through UCI Medical Center and affiliated institutions; intended for patients seeking access to investigational therapies.
• Center for Neural Circuit Mapping (CNCM) NIH-funded research center focused on neural circuit mapping using single-cell and spatial transcriptomics, hosting annual conferences and providing Viral Core, imaging, and bioinformatics services; serves neuroscience researchers and collaborators.
• Noel Drury, M.D. Institute for Translational Depression Discoveries Translational research institute focused on depression treatment, developing biomarker-guided approaches for precision psychiatry and antidepressant treatment selection; serves depression researchers and patients.

Quantifiable outcome

• 95% of residents are matched with their desired location upon completion of their residency
• +5 more outcomes

Named customers3 records

Segments7 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature7 records

Partnerships

20 partnerships are on record, tiered core and minor.

• Cajal ClubcoreStrategic or Co-development Partner · 17 August 2026Co-sponsor of annual CNCM Conference series (Neural Circuits in Health and Disease); the Cajal Club partners with UCI’s Center for Neural Circuit Mapping to host annual neuroscience conferences, with Dr. Gord Fishell leading 2026 conference organization.
• Max Planck Florida Institute for NeuroscienceminorStrategic or Co-development Partner · 17 August 2026Co-host partner for 2026 CNCM Conference on Neural Circuits in Health and Disease, alongside the Cajal Club and UCI Center for Neural Circuit Mapping.
• Broad Institute and Harvard Medical SchoolminorStrategic or Co-development Partner · 17 August 2026Conference co-sponsors for 2026 CNCM Conference ‘Neural Circuits in Health and Disease’, supporting UCI’s annual neuroscience conference series.
• Mass General Brigham-affiliated McLean HospitalcoreStrategic or Co-development Partner · 6 July 2026Co-lead institution for biomarker-guided depression treatment research published in Nature Mental Health. Diego A. Pizzagalli, founding director of UCI’s Noel Drury Institute, led the study in collaboration with McLean Hospital researchers.
• Noel Drury, M.D. Institute for Translational Depression DiscoveriescoreStrategic or Co-development Partner · 6 July 2026UCI-based institute focused on translational depression research; founded by Diego A. Pizzagalli, PhD, to advance biomarker-guided treatments for depression. Co-leads Nature Mental Health study with Mass General Brigham.
• Rady Children's Hospital of Orange County (CHOC)coreStrategic or Co-development Partner · 2 July 2026Clinical collaboration where UCI researchers helped save a patient at CHOC with novel antimicrobial approaches including bacteriophage therapy and the first U.S. use of cefepime–zidebactam. UCI’s Dr. Erlinda Ulloa oversaw treatment administration and management.
• Van Tyne Laboratory, University of PittsburghminorStrategic or Co-development Partner · 2 July 2026Collaborating laboratory for bacteriophage therapy development; collaborated with UCI’s Ulloa Lab to pursue bacteriophage therapy for the multidrug-resistant infection case at CHOC.
• U.S. Food and Drug Administration (FDA)coreStrategic or Co-development Partner · 2 July 2026FDA approved emergency access to cefepime–zidebactam for the first U.S. patient treatment case at CHOC, coordinated with UCI’s Dr. Erlinda Ulloa and CHOC’s Institutional Review Board.
• University of Ulm, GermanycoreStrategic or Co-development Partner · 23 June 2026International research collaboration with UC Irvine and Mayo Clinic Jacksonville on developing a new blood test for ALS diagnosis. Led by Sebastian Michels, MD from University of Ulm, contributing to the epigenetic methylation signature study using cell-free DNA.
• Mayo Clinic JacksonvillecoreStrategic or Co-development Partner · 23 June 2026International team collaboration on ALS blood test development. Led by Leonard Petrucelli and Mercedes Prudencio at Mayo Clinic Jacksonville, coordinating with UCI and University of Ulm researchers.
• Institute of Ecology and Biodiversity (IEB), ChileminorStrategic or Co-development Partner · 9 February 2026Co-organizer of UAMAA 2026 (Second International Conference on Unconventional Animal Models of Alzheimer’s Disease and Aging); organized with UCI’s Center for Neural Circuit Mapping, held in Santiago, Chile.
• Allen Institute for Brain SciencecoreStrategic or Co-development Partner · 18 August 2025Co-sponsor of 2025 CNCM Conference ‘The Changing Brain’ alongside CNCM and Cajal Club. Hongkui Zeng (Allen Institute) co-organizing the conference and serving on the External Advisory Board.
• International Association of Biomedical Sciences (IABS)minorStrategic or Co-development Partner · 7 December 2023IABS Forum 2023 held in Irvine, CA, focusing on neurodegenerative disorders including Alzheimer’s, Parkinson’s, Huntington’s diseases. UCI’s Dr. Xiangmin Xu spoke at the forum; IABS facilitates academic-industry collaboration for diagnostics and therapeutics development.
• Allen Institute for Brain SciencecoreStrategic or Co-development Partner · 21 August 2023Co-sponsor of 2023 CNCM Conference ‘Structure, Function and Development of Neural Circuits’ alongside Cajal Club and UC Irvine. Featured speakers and organizational committee members from the Allen Institute.
• Harvard UniversitycoreStrategic or Co-development Partner · 19 July 2023Co-principal investigator partnership on $3.8M BRAIN Initiative NIH grant (U24MH13326); Gordon Fishell, professor of neurobiology at Harvard, is co-PI alongside UCI’s Xiangmin Xu for scaling up viral targeting reagent production.
• Broad InstituteminorStrategic or Co-development Partner · 19 July 2023Collaboration partner on viral targeting reagent production and distribution project within the BRAIN Initiative; partners with UCI and Harvard to scale and optimize production and distribution processes.
• Western University of Health SciencesminorStrategic or Co-development Partner · 19 July 2023Partner institution on $3.8M BRAIN Initiative grant; scientists and trainees from Western University of Health Sciences in Pomona contribute to the viral targeting reagent production expansion.
• Morehouse School of MedicineminorStrategic or Co-development Partner · 19 July 2023Minority-serving institution partner on $3.8M BRAIN Initiative grant; contributes scientists and trainees to expand viral targeting reagent production and distribution alongside UCI, Harvard, and Broad Institute.
• University of MinnesotacoreStrategic or Co-development Partner · 15 June 2023Multi-institutional NIH-funded study on Alzheimer’s disease; Michael Koob (associate professor of laboratory medicine and pathology) and Timothy Ebner (department head and professor of neuroscience) from University of Minnesota are major investigators on the $10M NIH tau protein deposits project.
• UC San DiegocoreStrategic or Co-development Partner · 15 June 2023Collaborating institution on $10M NIH grant for Alzheimer’s research; Bing Ren, professor of cellular and molecular medicine at UC San Diego, is a major investigator on the tau protein deposits project alongside UCI’s Xiangmin Xu.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• UC San Diego School of Medicine: UC peer with overlapping research strengths in neuroscience, genomics, and translational medicine. Co-investigator with UCI on the $10M NIH tau protein study.
• UCSF School of Medicine: Another UC system medical school with comparable MD/PhD programs, NIH-funded biomedical research, and an affiliated academic medical center. Direct peer on admissions, research output, and federal grant competition.
• Mayo Clinic Alix School of Medicine: Collaborator with UCI on ALS blood test research and an academic medical center with comparable MD and graduate programs. Comparable in clinical research scale and translational science focus.
• UC Davis School of Medicine: UC system medical school with similar MD program, research portfolio, and LCME accreditation. Comparable in scale and California-focused clinical footprint.
• UCLA David Geffen School of Medicine: UC system peer with parallel structure of MD education, graduate programs, residency training, and a major academic medical center. Competes with UCI for federal funding, faculty recruits, and student applicants.

Regional players

• Keck School of Medicine of USC: Major California medical school with overlapping basic and clinical research portfolio. Competes regionally for NIH funding and California medical student applicants.
• Oregon Health & Science University (OHSU) School of Medicine: Public academic medical center with similar MD program size, NIH-funded research portfolio, and clinical-translational focus. Comparable in scale and structure to UCI.

Others

• Allen Institute for Brain Science: Co-sponsor of UCI's CNCM conferences and a leading neuroscience research organization. Not a medical school but a close collaborator in neural circuit mapping research.

Broad incumbents

• Harvard Medical School: Co-PI partner with UCI on the $3.8M BRAIN Initiative grant and a leading peer for NIH grant competition and faculty recruitment in neuroscience.
• Stanford School of Medicine: Top-tier U.S. medical school competing with UCI for NIH funding, top faculty, and elite MD/PhD applicants. Broader portfolio and larger endowment place it in the leading cluster.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/UCIMedSchool
• Facebookfacebook.com/UCIMedSchool
• LinkedInlinkedin.com/company/about

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UCI School of Medicine